MONOPRIL-HCT 20/12.5 (FOSINOPRIL SODIUM / HCTZ) ORAL TABLET

Side Effects & Adverse Event Reports


View Chart Data

21.1K

Adverse Events

160K

Side Effects

2008

Data Starting In

SymPedia Mobile App

Get our Mobile App for easy access to the latest reports on MONOPRIL-HCT 20/12.5 (FOSINOPRIL SODIUM / HCTZ) ORAL TABLET.

Understanding the potential Side Effects and Adverse Events of MONOPRIL-HCT 20/12.5 (FOSINOPRIL SODIUM / HCTZ) ORAL TABLET is essential for making informed health decisions. Our application provides in-depth reports based on real-world data, helping you explore how MONOPRIL-HCT 20/12.5 (FOSINOPRIL SODIUM / HCTZ) ORAL TABLET may affect your health.

View reports containing much more information including:

  • Age group - See how different age ranges experience side effects and adverse reactions.
  • Year - Track trends over time to understand changes in reported issues.
  • Biological sex - Compare how reports vary between men and women.
  • Weight - Examine the impact of body weight on side effects and adverse events.
Download Now

Frequently Asked Questions

Some questions about MONOPRIL-HCT 20/12.5 (FOSINOPRIL SODIUM / HCTZ) ORAL TABLET are asked frequently. We've answered the most frequent of those questions below

  • How many adverse events have been reported for MONOPRIL-HCT 20/12.5 (FOSINOPRIL SODIUM / HCTZ) ORAL TABLET?

    SymPedia shows MONOPRIL-HCT 20/12.5 (FOSINOPRIL SODIUM / HCTZ) ORAL TABLET adverse event reports for 21,109.

  • How many side effects have been reported for MONOPRIL-HCT 20/12.5 (FOSINOPRIL SODIUM / HCTZ) ORAL TABLET?

    SymPedia shows MONOPRIL-HCT 20/12.5 (FOSINOPRIL SODIUM / HCTZ) ORAL TABLET side effect reports for 160,004.

  • What year does the MONOPRIL-HCT 20/12.5 (FOSINOPRIL SODIUM / HCTZ) ORAL TABLET reporting data start?

    SymPedia reporting data on this page starts in 2008.

  • What years are included in the yearly chart for MONOPRIL-HCT 20/12.5 (FOSINOPRIL SODIUM / HCTZ) ORAL TABLET?

    SymPedia yearly chart data on this page covers 2008 to 2025.